Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma

Here we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotox...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Fatih M. Uckun
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	tumor microenvironment (TME) multiple myeloma (MM) bispecific T-cell engagers (BiTEs) bispecific antibodies (BsABs) bone marrow microenvironment (BMME) myeloid-derived suppressor cells (MDSC) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/11695cf4ab3a40e68a0db44dd99e9bf0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11695cf4ab3a40e68a0db44dd99e9bf0
record_format	dspace
spelling	oai:doaj.org-article:11695cf4ab3a40e68a0db44dd99e9bf02021-11-10T08:07:33ZDual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma2234-943X10.3389/fonc.2021.760382https://doaj.org/article/11695cf4ab3a40e68a0db44dd99e9bf02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.760382/fullhttps://doaj.org/toc/2234-943XHere we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotoxicity in an MHC-independent manner to malignant MM clones as well as immunosuppressive myeloid-derived suppressor cells (MDSC). T-cell engaging BsAB targeting the BCMA antigen may help delay disease progression in MM by destroying the MM cells. T-cell engaging BsAB targeting the CD38 antigen may help delay disease progression in MM by depleting both the malignant MM clones and the MDSC in the bone marrow microenvironment (BMME). BsABs may facilitate the development of a new therapeutic paradigm for achieving improved survival in MM by altering the immunosuppressive BMME. T-cell engaging BsiABs targeting the CD123 antigen may help delay disease progression in MM by depleting the MDSC in the BMME and destroying the MM stem cells that also carry the CD123 antigen on their surface.Fatih M. UckunFatih M. UckunFatih M. UckunFrontiers Media S.A.articletumor microenvironment (TME)multiple myeloma (MM)bispecific T-cell engagers (BiTEs)bispecific antibodies (BsABs)bone marrow microenvironment (BMME)myeloid-derived suppressor cells (MDSC)Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor microenvironment (TME) multiple myeloma (MM) bispecific T-cell engagers (BiTEs) bispecific antibodies (BsABs) bone marrow microenvironment (BMME) myeloid-derived suppressor cells (MDSC) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	tumor microenvironment (TME) multiple myeloma (MM) bispecific T-cell engagers (BiTEs) bispecific antibodies (BsABs) bone marrow microenvironment (BMME) myeloid-derived suppressor cells (MDSC) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Fatih M. Uckun Fatih M. Uckun Fatih M. Uckun Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
description	Here we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotoxicity in an MHC-independent manner to malignant MM clones as well as immunosuppressive myeloid-derived suppressor cells (MDSC). T-cell engaging BsAB targeting the BCMA antigen may help delay disease progression in MM by destroying the MM cells. T-cell engaging BsAB targeting the CD38 antigen may help delay disease progression in MM by depleting both the malignant MM clones and the MDSC in the bone marrow microenvironment (BMME). BsABs may facilitate the development of a new therapeutic paradigm for achieving improved survival in MM by altering the immunosuppressive BMME. T-cell engaging BsiABs targeting the CD123 antigen may help delay disease progression in MM by depleting the MDSC in the BMME and destroying the MM stem cells that also carry the CD123 antigen on their surface.
format	article
author	Fatih M. Uckun Fatih M. Uckun Fatih M. Uckun
author_facet	Fatih M. Uckun Fatih M. Uckun Fatih M. Uckun
author_sort	Fatih M. Uckun
title	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
title_short	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
title_full	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
title_fullStr	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
title_full_unstemmed	Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
title_sort	dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/11695cf4ab3a40e68a0db44dd99e9bf0
work_keys_str_mv	AT fatihmuckun dualtargetingofmultiplemyelomastemcellsandmyeloidderivedsuppressorcellsfortreatmentofchemotherapyresistantmultiplemyeloma AT fatihmuckun dualtargetingofmultiplemyelomastemcellsandmyeloidderivedsuppressorcellsfortreatmentofchemotherapyresistantmultiplemyeloma AT fatihmuckun dualtargetingofmultiplemyelomastemcellsandmyeloidderivedsuppressorcellsfortreatmentofchemotherapyresistantmultiplemyeloma
_version_	1718440349249044480

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma

Ejemplares similares